Latest Soft Tissue Sarcoma News

Page 1 of 2
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
Ada Torres
Ada Torres
26 Oct 2026
Immutep has narrowed eftilagimod alfa’s potential registration pathway to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma after identifying product differences between manufacturing scales used in earlier studies and TACTI-004. A new 200 L manufacturing run is planned, but replacement trials are not targeted to start until the second half of 2027 and remain subject to regulatory, funding and partnering decisions.
Ada Torres
Ada Torres
11 Sept 2026
Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.
Ada Torres
Ada Torres
15 Apr 2026
Immutep Limited has discontinued its pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer following an independent futility analysis, prompting a strategic reassessment of its clinical program and finances.
Ada Torres
Ada Torres
13 Mar 2026
Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.
Ada Torres
Ada Torres
29 Jan 2026
Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.
Ada Torres
Ada Torres
8 Dec 2025
Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.
Ada Torres
Ada Torres
13 Nov 2025
Immutep Limited’s Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma patients has exceeded its primary endpoint, showing a 51.5% median tumor hyalinization rate, more than triple the historical standard. These promising results, presented at ESMO 2025, suggest a potential breakthrough in a challenging cancer indication.
Ada Torres
Ada Torres
20 Oct 2025
Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.
Ada Torres
Ada Torres
13 Oct 2025
Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.
Ada Torres
Ada Torres
30 July 2025

Browse the archive

Full archive